Short Interest in Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Drops By 52.1%

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) saw a significant decline in short interest in June. As of June 15th, there was short interest totaling 3,994 shares, a decline of 52.1% from the May 31st total of 8,343 shares. Currently, 0.8% of the company’s stock are short sold. Based on an average daily volume of 48,201 shares, the days-to-cover ratio is currently 0.1 days.

Eloxx Pharmaceuticals Price Performance

Shares of NASDAQ ELOX opened at $12.10 on Thursday. Eloxx Pharmaceuticals has a 1-year low of $11.17 and a 1-year high of $17.50. The stock has a market capitalization of $8.32 million, a P/E ratio of -0.79 and a beta of -1,932.72. The stock has a 50-day moving average of $18.35.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.